This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ikeda, T. Articles by Hirokawa, K. Search for Related Content PubMed PubMed Citation Articles by Ikeda, T. Articles by Hirokawa, K.

Determination of Three Isoforms of the Receptor Activator of Nuclear Factor-B Ligand and Their Differential Expression in Bone and Thymus¹

Department of Pathology and Immunology (T.I., M.U., K.H.), Aging and Developmental Science, Graduate School, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo 113-8519, Japan; and Department of Bacterial and Blood Products (M.K.), National Institute of Infections Diseases, Shinjuku-ku, Tokyo 162, Japan

Address all correspondence and requests for reprints to: Tohru Ikeda, Department of Pathology and Immunology, Aging and Developmental Science, Graduate School, Tokyo Medical and Dental University, 1–5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan. E-mail: toru.pth2{at}med.tmd.ac.jp

The receptor activator of nuclear factor (NF)-B ligand [RANKL; also known as tumor necrosis factor-related activation-induced cytokine, osteoprotegerin ligand, and osteoclast differentiation factor] is known to bind with the receptor activator of NF-B (RANK) and act not only as a key factor for osteoclastogenesis but also as a regulator of lymphocyte development. In this study, we found two additional isoforms of RANKL. RANKL 2 has a shorter intracellular domain than the original RANKL (RANKL 1), and RANKL 3 lacks a transmembrane domain and was thought to act as a soluble form. In the bone marrow stromal cell line ST2 and preosteoblastic cell line MC3T3-E1, all three RANKL isoforms were detected, but the expression of RANKL 2 was preferentially suppressed by treatment with 1,25-dihydroxyvitamin D₃ and dexamethasone. In young adult thymus, CD4^-CD8^- double-negative cells were positive for all three isoforms, CD4⁺CD8⁺ double-positive cells were positive for RANKL 1 and RANKL 3 but negative for RANKL 2, and CD4⁺CD8^- and CD4^-CD8⁺ single-positive cells were positive for all three isoforms. Immunofluorescence analyses of NIH3T3 cells transfected with each RANKL isoform indicated that the three RANKL isoforms were translated, and RANKL 2 protein predominantly stayed in the endoplasmic reticulum and Golgi networks. These results indicate that there are three kinds of RANKL-RANK pathways. The presence of multiple RANKL-RANK pathways suggests a more complicated RANKL-RANK system for osteoclastogenesis or T cell differentiation than previously thought.

This article has been cited by other articles:

				G.E. Wise and G.J. King Mechanisms of Tooth Eruption and Orthodontic Tooth Movement Journal of Dental Research, May 1, 2008; 87(5): 414 - 434. [Abstract] [Full Text] [PDF]

				A. E. Kearns, S. Khosla, and P. J. Kostenuik Receptor Activator of Nuclear Factor {kappa}B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease Endocr. Rev., April 1, 2008; 29(2): 155 - 192. [Abstract] [Full Text] [PDF]

				T. Ukai, H. Yumoto, F. C. Gibson III, and C. A. Genco Macrophage-Elicited Osteoclastogenesis in Response to Bacterial Stimulation Requires Toll-Like Receptor 2-Dependent Tumor Necrosis Factor-Alpha Production Infect. Immun., February 1, 2008; 76(2): 812 - 819. [Abstract] [Full Text] [PDF]

				J.-M. Koh, Y.-S. Lee, C.-H. Byun, E.-J. Chang, H. Kim, Y. H. Kim, H.-H. Kim, and G. S. Kim {alpha}-Lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor {kappa}B ligand/osteoprotegerin ratio in human bone marrow stromal cells J. Endocrinol., June 1, 2005; 185(3): 401 - 413. [Abstract] [Full Text] [PDF]

				J. L. Roccisana, N. Kawanabe, H. Kajiya, M. Koide, G. D. Roodman, and S. V. Reddy Functional Role for Heat Shock Factors in the Transcriptional Regulation of Human RANK Ligand Gene Expression in Stromal/Osteoblast Cells J. Biol. Chem., March 12, 2004; 279(11): 10500 - 10507. [Abstract] [Full Text] [PDF]

				U. Heider, I. Zavrski, C. Jakob, C. Fleissner, O. Sezer, A. C. W. Zannettino, B. Pan, A. N. Farrugia, G. J. Atkins, and L. B. To Identification and Clinical Relevance of Receptor Activator of Nuclear Factor {kappa}B Ligand Expression of Myeloma Cells Cancer Res., January 15, 2004; 64(2): 773 - 775. [Full Text] [PDF]

				U. Heider, C. Langelotz, C. Jakob, I. Zavrski, C. Fleissner, J. Eucker, K. Possinger, L. C. Hofbauer, and O. Sezer Expression of Receptor Activator of Nuclear Factor {kappa}B Ligand on Bone Marrow Plasma Cells Correlates with Osteolytic Bone Disease in Patients with Multiple Myeloma Clin. Cancer Res., April 1, 2003; 9(4): 1436 - 1440. [Abstract] [Full Text] [PDF]